The Changing Landscape of Breast Cancer: How Biology Drives TherapyReportar como inadecuado




The Changing Landscape of Breast Cancer: How Biology Drives Therapy - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

1

Hematology Oncology, University of New Mexico Comprehensive Cancer Center, University of New Mexico, 1201 Camino de Salud N.E., MSC 07-4025, Albuquerque, NM 87131, USA

2

New Mexico Cancer Care Alliance, UNM Comprehensive Cancer Center Multidisciplinary Breast Cancer Clinic andProgram, University of New Mexico, 1201 Camino de Salud N.E., MSC 07-4025, Albuquerque, NM 87131, USA



These authors contributed equally to this work.





*

Author to whom correspondence should be addressed.



Academic Editors: Daniel M.-Y. Sze and William Chi-shing Cho

Abstract Breast cancer is the most prevalent life-threatening cancer in women. Optimizing therapy to increase cure rates in early stage disease, and improving life expectancy and palliation for advanced stages, are goals driving major areas of research. The armamentarium of targeted treatments for breast cancer is ever expanding as understanding of breast cancer biology deepens. A revolution in our treatment was heralded a decade ago by the introduction of trastuzumab for human epidermal receptor-2 positive HER2+ disease resulting in remarkable reductions in recurrence and improvements in overall survival OS. Advances continue to be made in other breast cancer subtypes targeting key activating pathways for therapeutic development. However, for these other targeted agents, improvement in OS has been elusive. This article focuses on the development of targeted therapy in breast cancer focusing primarily on the last 5 years, to illustrate that as we understand the complex pathways allowing the dysregulated cell to become malignant, it also propels us closer towards the promise of precision and personalized medicine. View Full-Text

Keywords: breast cancer; targeted therapy; PI3K-AKT-mTOR Inhibitors; cyclin-dependent kinase CDK inhibitors; pertuzumab; Ado-trastruzumab-emtansine; angiogenesis inhibitors; poly ADP-ribose polymerases PARP inhibitors breast cancer; targeted therapy; PI3K-AKT-mTOR Inhibitors; cyclin-dependent kinase CDK inhibitors; pertuzumab; Ado-trastruzumab-emtansine; angiogenesis inhibitors; poly ADP-ribose polymerases PARP inhibitors





Autor: Sarah Friend 1,† and Melanie Royce 2,†,*

Fuente: http://mdpi.com/



DESCARGAR PDF




Documentos relacionados